IDH-1R132H mutation status in diffuse glioma patients: implications for classification

Abstract

WHO2007 grading of diffuse gliomas in adults is well-established. However, IDH mutations make classification of gliomas according to the WHO2007 edition controversial. Here, we characterized IDH-1R132H mut status in a cohort of 670 adult patients with different WHO2007 grades of diffuse glioma. Patient characteristics, clinical data and prognoses were obtained from medical records. Patients with IDH-1R132H mut were younger and had better clinical outcomes than those without mutations. Differences in age among patients with astrocytomas of different WHO2007 grades were eliminated after patients were grouped based on IDH-1R132H status. IDH-1R132H mut was present more often in patients with lower Ki-67 and MGMT protein levels and higher mutant p53 levels. Ki-67 was also strongly associated with WHO2007 grade independently of IDH-1R132H mut status. Moreover, patients with Ki-67<30 survived longer than those with Ki-67≥30, regardless of IDH-1R132H mut status. Patients in the IDH-1R132H mut group with lower MGMT protein levels also had better clinical outcomes than those in other groups. Our results indicate that to better treat gliomas, IDH mutation status should be included when determining WHO2007 grade in glioma patients.

Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival

“…Immunohistochemistry was used for detection of IDH mutations. The procedures were performed as described previously [ 9 ] using primary antibodies against IDH1 R132H (Dianova 1:100) . The cutoff values were 10% for IDH-1 R132H mut .…”

“…The discovery that isocitrate dehydrogenase (IDH) mutations are more common in sGBMs was one of the most significant advancements in the understanding of gliomas [ 3 , 4 ]. Patients with glioblastomas carrying IDH mutations or wildtype IDH, exhibited large differences in prognosis, age, and genetic alternations [ 5 – 9 ].…”

Detection of programmed death ligand 1 protein and CD8+ lymphocyte infiltration in plurihormonal pituitary adenomas

“…The immunohistochemistry was performed as we did previously. [ 12 ] Immunostaining of GH and PRL was positive (Fig Supplement 1), suggesting a PRL-GH secreting plurihormonal tumor. Next, the tumor sample obtained from the operation was used to evaluate the PD-L1 expression and CD8 + lymphocytes infiltration in the tumor tissues.…”

An Insight into the Increasing Role of LncRNAs in the Pathogenesis of Gliomas

“…Additionally, in vitro studies have strongly suggested that the altered expression of lncRNAs during genome mutation or genotoxic stress is involved in multiple neuro-oncological disorder-associated cellular processes. Isocitrate dehydrogenase 1 (IDH1) mutations have been shown to be an important prognostic marker for patients with gliomas ( Cai et al, 2016 ; Wang P.F. et al, 2016 ).…”